Citigroup Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $100

Benzinga Newsdesk www.benzinga.com Negative 46.1%

Neg 46.1% Neu 0% Pos 0%

Citigroup analyst Eric Joseph maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $115 to $100.